Literature DB >> 17154663

Intravenous ibandronate in the treatment of osteoporosis: profile report.

Katherine F Croom1, Lesley J Scott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17154663     DOI： 10.2165/00002512-200623120-00006

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


× No keyword cloud information.
  10 in total

1.  Treatment of postmenopausal osteoporosis.

Authors:  A Cranney
Journal:  BMJ       Date:  2003-08-16

2.  Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.

Authors:  Pierre D Delmas; Silvano Adami; Cezary Strugala; Jacob A Stakkestad; Jean-Yves Reginster; Dieter Felsenberg; Claus Christiansen; Roberto Civitelli; Marc K Drezner; Robert R Recker; Michael Bolognese; Claire Hughes; Daiva Masanauskaite; Penelope Ward; Philip Sambrook; David M Reid
Journal:  Arthritis Rheum       Date:  2006-06

3.  Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society.

Authors: 
Journal:  Menopause       Date:  2006 May-Jun       Impact factor: 2.953

4.  Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.

Authors:  D Thiébaud; P Burckhardt; H Kriegbaum; H Huss; H Mulder; J R Juttmann; K H Schöter
Journal:  Am J Med       Date:  1997-10       Impact factor: 4.965

5.  Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.

Authors:  Roland D Chapurlat
Journal:  Treat Endocrinol       Date:  2005

Review 6.  Intravenous ibandronate: in the treatment of osteoporosis.

Authors:  Katherine F Croom; Lesley J Scott
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.

Authors:  J A Stakkestad; L I Benevolenskaya; J J Stepan; A Skag; A Nordby; E Oefjord; A Burdeska; I Jonkanski; P Mahoney
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

8.  Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Authors:  Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741

9.  Efficacy and safety of ibandronate given by intravenous injection once every 3 months.

Authors:  S Adami; D Felsenberg; C Christiansen; J Robinson; R S Lorenc; P Mahoney; K Coutant; R C Schimmer; P D Delmas
Journal:  Bone       Date:  2004-05       Impact factor: 4.398

10.  Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.

Authors:  R Recker; J A Stakkestad; C H Chesnut; C Christiansen; A Skag; A Hoiseth; M Ettinger; P Mahoney; R C Schimmer; P D Delmas
Journal:  Bone       Date:  2004-05       Impact factor: 4.398
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.